Skip to main content
    T

    Tango Therapeutics Inc (TNGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $24.17
    -1.33 (-5.22%)

    Market Cap: $4.32B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tango Therapeutics Inc (TNGX) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Tango Therapeutics (TNGX) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Tango Therapeutics reported EPS of -$0.39, below the -$0.34 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(11/22)
    Avg Surprise
    +16.37%

    Upcoming Estimates

    Reports Mar 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.41
    Range-$0.47 - -$0.33
    15 analysts
    Revenue Consensus
    N/A
    RangeN/A
    14 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.43
    Range-$0.50 - -$0.34
    4 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.36-18.8%
    60d ago-$0.37-15.0%
    30d ago-$0.37-15.0%
    7d ago-$0.38-14.4%
    Current-$0.43
    Revenue Consensus
    $1.58M
    RangeN/A
    5 analysts

    Next Report

    TNGX has an expected report date of Mar 3, 2027.

    Earnings History

    Of the 22 quarters below that had an estimate, TNGX beat 11, missed 10 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2025, when EPS landed 285.71% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.39-$0.34-$0.42 - -$0.30-14.71%Miss-400.0%121 up, 2 downNov 9, 2026N/A
    Jun 30, 2026-$0.37-$0.31-$0.35 - -$0.30-19.35%MissN/A113 up, 1 downAug 10, 2026N/A
    Mar 31, 2026-$0.32-$0.30-$0.38 - -$0.28-7.85%MissN/A110 up, 1 downMay 13, 2026N/A
    Dec 31, 2025-$0.29-$0.33-$0.52 - -$0.24+12.12%BeatN/A92 up, 0 downMar 5, 2026N/A
    Sep 30, 2025$0.13-$0.07-$0.40 - $0.13+285.71%BeatN/A85 up, 0 downNov 4, 2025$53.81M
    Jun 30, 2025-$0.35-$0.34-$0.40 - -$0.27-2.94%MissN/A81 up, 0 downAug 5, 2025$3.18M
    Mar 31, 2025-$0.36-$0.35-$0.38 - -$0.28-2.86%MissN/A70 up, 1 downMay 12, 2025$5.39M
    Dec 31, 2024-$0.34-$0.34-$0.37 - -$0.25+0.82%BeatN/A95 up, 1 downFeb 27, 2025$4.12M
    Sep 30, 2024-$0.27-$0.37-$0.52 - -$0.30+27.03%BeatN/A100 up, 0 downNov 6, 2024$11.61M
    Jun 30, 2024-$0.24-$0.35-$0.46 - -$0.29+31.43%BeatN/A101 up, 0 downAug 7, 2024$19.88M
    Mar 31, 2024-$0.35-$0.31-$0.33 - -$0.28-12.90%MissN/A90 up, 0 downMay 8, 2024$6.47M
    Dec 31, 2023-$0.32-$0.28-$0.32 - -$0.25-14.29%MissN/A80 up, 0 downMar 18, 2024$5.43M
    Sep 30, 2023-$0.23-$0.34-$0.37 - -$0.31+32.35%BeatN/A60 up, 0 downNov 8, 2023$10.73M
    Jun 30, 2023-$0.23-$0.34-$0.39 - -$0.29+32.35%BeatN/A50 up, 0 downAug 7, 2023$14.60M
    Mar 31, 2023-$0.32-$0.35-$0.37 - -$0.33+8.57%BeatN/A60 up, 0 downMay 9, 2023$5.77M
    Dec 31, 2022-$0.33-$0.35-$0.37 - -$0.34+5.71%BeatN/A60 up, 0 downMar 27, 2023$6.41M
    Sep 30, 2022-$0.33-$0.32-$0.36 - -$0.30-3.13%MissN/A60 up, 0 downNov 10, 2022$6.92M
    Jun 30, 2022-$0.28-$0.32N/A+12.50%BeatN/AN/A0 up, 0 downAug 10, 2022$5.77M
    Mar 31, 2022-$0.29-$0.27-$0.33 - -$0.24-7.41%MissN/A50 up, 0 downMay 11, 2022$5.76M
    Dec 31, 2021-$0.25-$0.27-$0.30 - -$0.25+7.41%BeatN/A50 up, 0 downMar 28, 2022$5.72M
    Sep 30, 2021-$0.28-$0.28-$0.37 - -$0.220.00%In lineN/A5N/ANov 9, 2021$6.79M
    Jun 30, 2021-$0.16-$0.15N/A-10.34%MissN/AN/AN/AJul 16, 2021$18.15M
    Mar 31, 2021-$0.01N/AN/AN/AN/AN/AN/AN/AMay 14, 2021$6.39M
    Dec 31, 2020$0.00N/AN/AN/AN/AN/AN/AN/AMar 31, 2021$9.14M
    Sep 30, 2020$0.00N/AN/AN/AN/AN/AN/AN/ANov 13, 2020N/A
    Jun 30, 2020Not reportedN/AN/AN/ANot reportedN/AN/AN/AJul 30, 2020$5.06M
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.87, after -$1.20 the year before. It was -$0.01 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.87N/A
    Dec 31, 2024-$1.20N/A
    Dec 31, 2023-$1.10N/A
    Dec 31, 2022-$1.23N/A
    Dec 31, 2021-$0.70N/A
    Dec 31, 2020-$0.01N/A

    Frequently Asked Questions About TNGX

    When is Tango Therapeutics's next earnings date?

    Tango Therapeutics's next earnings report is expected for Mar 3, 2027.

    Did TNGX beat earnings estimates last quarter?

    No. Tango Therapeutics reported EPS of -$0.39 for the quarter ended Sep 30, 2026, below the -$0.34 estimate by 14.71%.

    What EPS do analysts expect from TNGX next quarter?

    The consensus EPS estimate for Tango Therapeutics for the quarter ending Dec 31, 2026 is -$0.41 from 15 analysts, with estimates from -$0.47 to -$0.33.

    How often does TNGX beat earnings estimates?

    Tango Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +31.37%.